A detailed history of Primecap Management CO transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Primecap Management CO holds 18,867,435 shares of BMRN stock, worth $1.24 Billion. This represents 0.99% of its overall portfolio holdings.

Number of Shares
18,867,435
Previous 18,790,085 0.41%
Holding current value
$1.24 Billion
Previous $1.55 Billion 14.27%
% of portfolio
0.99%
Previous 1.14%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$69.02 - $93.84 $5.34 Million - $7.26 Million
77,350 Added 0.41%
18,867,435 $1.33 Billion
Q2 2024

Aug 09, 2024

BUY
$74.43 - $92.22 $5.67 Million - $7.03 Million
76,190 Added 0.41%
18,790,085 $1.55 Billion
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $25.1 Million - $29.7 Million
299,521 Added 1.63%
18,713,895 $1.63 Billion
Q4 2023

Feb 09, 2024

BUY
$76.22 - $98.51 $597,183 - $771,825
7,835 Added 0.04%
18,414,374 $1.78 Billion
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $1.95 Million - $2.17 Million
22,920 Added 0.12%
18,406,539 $1.63 Billion
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $12.2 Million - $14.1 Million
140,190 Added 0.77%
18,383,619 $1.59 Billion
Q1 2023

May 15, 2023

BUY
$87.74 - $117.27 $58.1 Million - $77.7 Million
662,570 Added 3.77%
18,243,429 $1.77 Billion
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $3.61 Million - $4.85 Million
-44,646 Reduced 0.25%
17,580,859 $1.82 Billion
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $4.35 Million - $5.14 Million
-52,980 Reduced 0.3%
17,625,505 $1.49 Billion
Q2 2022

Aug 11, 2022

SELL
$71.48 - $86.85 $7.22 Million - $8.77 Million
-100,985 Reduced 0.57%
17,678,485 $1.47 Billion
Q1 2022

May 11, 2022

SELL
$74.28 - $92.69 $1.88 Million - $2.35 Million
-25,310 Reduced 0.14%
17,779,470 $1.37 Billion
Q4 2021

Feb 11, 2022

SELL
$71.72 - $91.47 $9.51 Million - $12.1 Million
-132,550 Reduced 0.74%
17,804,780 $1.57 Billion
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $1.18 Million - $1.34 Million
-15,736 Reduced 0.09%
17,937,330 $1.39 Billion
Q2 2021

Aug 10, 2021

SELL
$75.51 - $84.79 $15.5 Million - $17.4 Million
-204,728 Reduced 1.13%
17,953,066 $1.5 Billion
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $734,820 - $891,754
9,833 Added 0.05%
18,157,794 $1.37 Billion
Q4 2020

Feb 08, 2021

SELL
$72.61 - $90.2 $3.16 Million - $3.93 Million
-43,580 Reduced 0.24%
18,147,961 $1.59 Billion
Q3 2020

Nov 13, 2020

BUY
$71.87 - $131.03 $22.1 Million - $40.3 Million
307,570 Added 1.72%
18,191,541 $1.38 Billion
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $5.9 Million - $9.22 Million
74,204 Added 0.42%
17,883,971 $2.21 Billion
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $106 Million - $143 Million
1,480,447 Added 9.07%
17,809,767 $1.5 Billion
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $75 Million - $101 Million
1,167,246 Added 7.7%
16,329,320 $1.38 Billion
Q3 2019

Nov 13, 2019

BUY
$67.4 - $85.11 $59.2 Million - $74.8 Million
878,321 Added 6.15%
15,162,074 $1.02 Billion
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $7.46 Million - $8.72 Million
92,880 Added 0.65%
14,283,753 $1.22 Billion
Q1 2019

May 14, 2019

BUY
$84.2 - $98.62 $479,940 - $562,134
5,700 Added 0.04%
14,190,873 $1.26 Billion
Q4 2018

Feb 12, 2019

SELL
$80.14 - $106.07 $1.87 Million - $2.47 Million
-23,312 Reduced 0.16%
14,185,173 $1.21 Billion
Q3 2018

Nov 13, 2018

SELL
$93.92 - $105.72 $3.03 Million - $3.42 Million
-32,304 Reduced 0.23%
14,208,485 $1.38 Billion
Q2 2018

Aug 13, 2018

BUY
$76.01 - $99.03 $36 Million - $47 Million
474,250 Added 3.44%
14,240,789 $1.34 Billion
Q1 2018

May 14, 2018

BUY
$77.67 - $92.63 $273 Million - $326 Million
3,521,244 Added 34.37%
13,766,539 $1.12 Billion
Q4 2017

Feb 13, 2018

BUY
$80.76 - $95.13 $49 Million - $57.7 Million
606,651 Added 6.29%
10,245,295 $914 Million
Q3 2017

Nov 13, 2017

BUY
$80.6 - $94.95 $777 Million - $915 Million
9,638,644
9,638,644 $897 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.